Monograph Details
|
|
Hematology
> White blood cell disorders
|
|
NEULASTA |
| Manufacturer |
|
Amgen, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Granulocyte colony stimulating factor. |
| Generic Name |
|
Pegfilgrastim (polyethylene glycol/filgrastim conjugate) 6mg/0.6mL soln; SC inj; preservative-free. |
| Indications |
|
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia. |
| Children |
|
Not recommended. |
| Adults |
|
Do not give between 14 days before and 24 hours after chemotherapy. Adolescents <45 kg: not recommended. ≥45 kg: 6 mg SC once per chemotherapy cycle. |
| Contraindications |
|
Do not use for peripheral blood progenitor cell (PBPC) mobilization. Hypersensitivity to E. coli-derived products. |
| Precautions |
|
Monitor CBC and platelets before and during therapy. Monitor for splenomegaly/splenic rupture and for adult respiratory distress syndrome (ARDS); suspend until ARDS resolves if fever or lung infiltrates occur. Sickle cell disease (may cause sickle cell crisis). Myeloid malignancies. Myelodysplasia. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Caution with drugs that cause delayed myelosuppression (eg, nitrosoureas, mitomycin C), or increase release of neutrophils (eg, lithium), antimetabolites (eg, 5-FU), and radiation therapy. |
| Adverse Reactions |
|
Bone pain, anaphylaxis, ARDS; splenic rupture (rare). |
| How Supplied |
|
Prefilled syringe—1 |
|
|
|
|
